Back to top
more

Cardiff Oncology (CRDF)

(Real Time Quote from BATS)

$2.62 USD

2.62
222,693

+0.04 (1.55%)

Updated Nov 19, 2024 10:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 7.41% and 32%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aadi Bioscience (AADI) delivered earnings and revenue surprises of 0% and 10.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -4% and 35.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: Navios Maritime, Coinbase Global, Virtu Financial in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 12% and 86.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Cardiff Oncology (CRDF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why

by Zacks Equity Research

Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.

Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Cardiff Oncology (CRDF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?

by Zacks Equity Research

Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Cardiff Oncology (CRDF) have what it takes to be a top stock pick for momentum investors? Let's find out.

Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 19.23% and 108%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of 166.67% and 163.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 100% and 1.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of 39.67% and 1.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Regenxbio (RGNX): Can Its 11.7% Jump Turn into More Strength?

by Zacks Equity Research

Regenxbio (RGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Cardiff Oncology (CRDF) Loses -29.75% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Cardiff Oncology (CRDF) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 7.41% and 44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -4.35% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of 6.94% and 25.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -8.70% and 10.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Has Cardiff Oncology (CRDF) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Cardiff Oncology (CRDF) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 20% and 70.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 25.93% and 24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 4% and 21.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Regenxbio (RGNX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.